BioIVT’s Post

Today marks the start of the 35th Annual European Congress of Pathology (ECP)! Advances in technology and science continue to transform our knowledge of many diseases.1,2 ECP brings together experts from across the globe to discuss these developments and how they can inform targeted treatment approaches. Stay tuned for more over the coming days! #ESPCongress #ECP2023Dublin

Am Not surprised at all too. This is well Expected from A world class HTA pioneer like NICE. It’s fair to ask for the patient segment-specific cost effectiveness data and the recommended standards. Just screening and putting more people on a pathway only increases the cost and might reduce/dilute QALY outcomes, hence an RCT type study is required. And I don’t buy the argument Ex-NICE assessments are any different or lighter, if they are then one should be worried of the risks, clinical and legal.

Current manual methods for HER2 assessment are fraught with challenges. Significant challenges are the inter- and intra-reader variability and the high proportion of inconclusive cases requiring additional testing for a definitive diagnosis. These inconclusive cases pose a considerable challenge, adding costs for reflex testing, and slowing down the diagnostic process, thereby creating uncertainty for patients and clinicians alike. In this context, AI-driven precision pathology has emerged as a promising solution 💡 Read our whitepaper to learn more about Visiopharm’s IVDR-cleared solution for HER2 assessment: https://hubs.ly/Q02ljrBn0

Have you heard EverLift® Submucosal Lifting Agent does not produce artifacts post EMR/ESD? Laborie’s post-market clinical follow-up study generated significant data that evaluated the pathology results of the effects of endoscopic mucosal resection and endoscopic submucosal dissection. Download the whitepaper to learn more about the key findings: https://hubs.li/Q02DpBTx0 #ForDignityForLife #Laborie

In the realm of #standardizedtesting within speech-language pathology, the standard score is often the first metric we encounter. But what insights does it truly offer us about our clients? The standard score is derived from the raw score and adjusted to fit the normal distribution curve, with a mean of 100 and a standard deviation of 15. A score of 85, for instance, places a client one standard deviation below the mean. It's a crucial data point, yet it's merely a single snapshot influenced by numerous factors during the testing process. As we delve deeper into the various scores obtained from standardized tests, we must critically evaluate their utility. Is the standard score the most effective tool for interpretation? How does it shape our diagnostic decision-making? Join us in this comprehensive exploration of test scores and their implications. Engage with us, share your experiences, and let's enhance our collective understanding. Your perspective is invaluable. 👉 Visit our website to subscribe to our newsletter for more in-depth discussions and insights. #StandardizedTesting #SpeechLanguagePathology #DiagnosticDecisionMaking #ClinicalAssessment

You won't want to miss PathGroup CMO and Concentriq user Derek Welch, MD, FCAP when he takes the stage today at 5:30PM. He'll share a firsthand account of his laboratory's journey adopting #digitalpathology at scale and preparing for the AI-powered future. 

The Medical College of Wisconsin utilizes the GO Pathology Workbench to streamline variant review and analysis. Since implementation, the MCW laboratory has improved the efficiency of somatic variant analysis in 2 main areas—turnaround time (TAT) and comprehensive report generation. To learn more about the impact of this partnership, read the study here: https://ow.ly/BaVv50Qjjv6 #precisiononcology

"When we think we know all the answers, we stop looking for them."   -      Eric Barker, from "Barking Up the Wrong Tree: The Surprising Science Behind Why Everything You Know About Success Is (Mostly) Wrong" As our experience with dynamic "all organ" imaging grows, we continue to question how and when to best incorporate it into our clinical protocols to provide the optimum convenience and diagnostic outcomes for our patients. Approaches to improving detection of prostate bed recurrences through early imaging (See: Uprimny, C. et al. EJNMMI 2017;44:1647–55) or forced diuresis (See: Uprimny, C. et al. J Nucl Med 2021; 62:1550–57), provide options for conventional field-of-view scanners but still aren't widely used, seemingly for workflow reasons. We think the ability to compare kinetics of uptake or clearance of activity may help to better characterize abnormalities outside the pelvis as well as a plethora of physiologically and pathologically relevant findings not apparent on delayed imaging. However, I admit, we are still learning and have many questions still to answer. In the case below, anastomotic and right pedicle recurrences are seen very early in a 10-minute dynamic series reconstructed as 1-minute frames, but difficult to  assess on delayed imaging while a pulmonary metastasis has the same kinetics as the prostate bed disease, increasing confidence in its nature.

The Medical College of Wisconsin utilizes the GO Pathology Workbench to streamline variant review and analysis. Since implementation, the MCW laboratory has improved the efficiency of somatic variant analysis in 2 main areas—turnaround time (TAT) and comprehensive report generation. To learn more about the impact of this partnership, read the study here: https://ow.ly/ECpR50Pyz8u #precisiononcology

Two new Letters to the Editor! Follow the discussion regarding the recent publication about mixed connective tissue disease. Is MCTD a distinct entity? 🔸Original Article: This study shows that MCTD is a distinct entity that can be classified using either Kasukawa or Sharp criteria and that only 25.8 per cent of patients progress to a dCTD during follow-up. 🔸Letter to the Editor: If their clinical presentation is similar and the only difference is the antibody subtype, should we not lump these disorders within the same nosological entity with a common name — that is, SSc? The cohort from Chevalier et al. offers a unique opportunity to explore this question and enrich the debate on the existence of MCTD as a distinct entity. 🔸Authors Reply: We strongly disagree with the proposal to lump MCTD and SSc under the same name. Such a decision would be a simplistic mistake, whereas striving to enhance both the SSc and MCTD classifications could be a common objective. 🔗Original Article: https://lnkd.in/djRPsKcV 🔗🔗Letter to the Editor: https://lnkd.in/dKBdX7Hi 🔗🔗🔗Authors reply: https://lnkd.in/d_hWjz2S #Sjogrens #systemic #sclerose